TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02001480

Intervention type: DEVICE
Group type: OTHER
Intervention: 12 lead Holter
Description: 12 lead Holter measurements will be performed for 7 days

Intervention type: DEVICE
Group type: OTHER
Intervention: CGM Continuous Glucose Monitoring
Description: CGM will be performed continously for 7 days
Study: NCT00926653

Intervention type: DRUG
Intervention: Escitalopram
Description: 10 to 20 mg daily as part of another study in which participants are enrolled
Study: NCT02983227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
Study: NCT06404580

Intervention type: PROCEDURE
Intervention: R anastomosis
Description: R anastomosis

Intervention type: PROCEDURE
Intervention: R anastomosis
Description: R anastomosis
Study: NCT04156308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) - Temp1
Description: A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
Study: NCT01447979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable artificial pancreas system with Control-To-Range algorithms
Description: The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
Study: NCT05322265

Intervention type: PROCEDURE
Intervention: laparoscopic surgery for renal and adrenal diseases
Description: type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
Study: NCT04682431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 1
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 2
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 3
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 4
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 5
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 6
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 7
Description: Dose of PY159 as a single agent given in a standard 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 1
Description: Dose of PY159 and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 2
Description: Dose of PY159 and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 3
Description: Dose of PY159 and given in combination with pembrolizumab
Study: NCT04156308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) - Temp1
Description: A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercises
Description: A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercises
Description: A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercises
Description: A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
Study: NCT03676062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs applied three sessions per week, totally six week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs applied three sessions per week, totally six week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs applied three sessions per week, totally six week.
Study: NCT01417312

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules with 160 mg Teavigo (at least 94% EGCG)
Description: Daily intake of 600 mg EGCG for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of placebo capsules for 3 months
Study: NCT01446822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
Description: Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
Study: NCT03030599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-258
Description: JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
Study: NCT04682431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 4
Description: Dose of PY159 and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose expansion cohort
Description: Dose of PY159 as a single agent given for predefined tumor histology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 1
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT02487563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: immunoglobulin, glucocorticoid etc
Study: NCT01130766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery (SRS)
Description: Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
Study: NCT02784535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: norepinephrine transporter inhibitor
Study: NCT04682431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 2
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 3
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT02784535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04682431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 4
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 5
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose expansion cohort 6
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT03806218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar RFA
Description: Bipolar RFA in which RF currents flow between two electrodes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SM-RFA
Description: Monopolar RFA using multiple electrodes with switching mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin internally cooled-wet electrodes
Description: Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Separable clustered electrodes
Description: A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
Study: NCT04301518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention strategy
Description: * Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation
Study: NCT04386668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let It Out (LIO)-C
Description: Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral writing control
Description: Participants complete three online 20-minute writing sessions in response to neutral writing prompts
Study: NCT02328807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-Frequency Ablation (RFA)
Description: RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
Study: NCT01448265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation.
Description: Cryoballoon ablation using a novel circular mapping catheter.
Study: NCT03396653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer-delivered Weight Maintenance
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professionally-Delivered Weight Maintenance
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
Study: NCT04584112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
Study: NCT03012997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen 100%
Study: NCT03389932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Guided
Description: Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
Study: NCT04584112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 420 mg administered by IV infusion Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 420 mg administered by IV infusion Q2W.
Study: NCT04158167

Intervention type: DRUG
Group type: OTHER
Intervention: oxytocin
Description: 24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
Study: NCT04584112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
Study: NCT02943954

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography guided PCI
Study: NCT04584112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
Study: NCT04567745

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Retinal fundus photography
Description: Fundus photographs
Study: NCT02943954

Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional Flow Reserve (FFR)
Study: NCT02340429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DE500 Digital Video Otoscope
Study: NCT02204215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric acupuncture
Description: Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
Study: NCT02641795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive robotic cochlear implantation
Study: NCT02204215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative
Description: General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
Study: NCT01721967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study: NCT00626587

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)
Description: The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
Study: NCT02076932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning
Description: After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spinning
Description: After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
Study: NCT03440580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BOOSTH
Description: BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
Study: NCT02516371

Intervention type: OTHER
Group type: OTHER
Intervention: lymphocyte
Description: To evaluate the subpopulation of lymphocytes in cancer patients
Study: NCT02223299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tyrosine
Description: 6g/d daily for 30 days
Study: NCT01116271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 50 or 75mg, capsules, PO, BID, 28 days
Study: NCT04146454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-based balance exercises
Description: A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
Study: NCT04521439

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 18F-florbetapir PET+MRSI
Description: PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-florbetapir PET+MRSI
Description: PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
Study: NCT06379022

Intervention type: BEHAVIORAL
Intervention: Plaque control
Description: Subjects are motivated for optimal oral hygiene

Intervention type: BEHAVIORAL
Intervention: Plaque control
Description: Subjects are motivated for optimal oral hygiene
Study: NCT01116271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2, IV, Day 1\& 15 of each cycle
Study: NCT02452944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve stimulator (stimuplex HNS12)
Description: whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulator (stimuplex HNS12)
Description: whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
Study: NCT00391768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir (Tamiflu®)
Description: Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
Study: NCT03686059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: daily intake of 250 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctal plug
Description: punctal plug will be inserted in inferior punctum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctal plug
Description: punctal plug will be inserted in inferior punctum
Study: NCT00659581

Intervention type: DRUG
Intervention: Telmisartan
Description: Oral administration